Designing for Paediatric & Young Adult CKD Earlier to Meet Regulatory Expectations & Access Cleaner Development Populations (e.g. FSGS, Alport Syndrome)

• Integrating paediatric development planning earlier rather than treating it as a postapproval requirement
• Recognizing young adults with CKD who may carry fewer confounding comorbidities and background medications
• Adapting endpoints and trial designs for younger and more slowly progressing populations

Speakers: